Abstract | BACKGROUND AND PURPOSE: METHODS: In a multicenter, double-blind, randomized, placebo-controlled Phase II trial, 40 patients with ischemic stroke were treated with either placebo or active drug between 3 and 12 hours after symptom onset in a dose-finding design. Ten patients received placebo, 6 patients received a total dose of 2 mg/kg, 12 patients received a total dose of 3 mg/kg, and 12 patients received a total dose of 4 mg/kg. We studied the pharmacodynamics of microplasmin and its effect on the clinical and hemodynamic parameters of the patients. MRI was used as a surrogate marker and matrix metalloproteinases serum concentrations were used as markers of neurovascular integrity. The study was underpowered to detect clinical efficacy. RESULTS:
Microplasmin induced reversible effects on markers of systemic thrombolysis and neutralized alpha(2)-antiplasmin by up to 80%. It was well tolerated with one of 30 treated patients developing a fatal symptomatic intracerebral hemorrhage. No significant effect on reperfusion rate or on clinical outcome was observed. Matrix metalloproteinase-2 levels were reduced in microplasmin-treated patients. CONCLUSIONS:
Microplasmin was well tolerated and achieved neutralization of alpha(2)-antiplasmin. Further studies are warranted to determine whether microplasmin is an effective therapeutic agent for ischemic stroke.
|
Authors | Vincent N S Thijs, Andre Peeters, Milan Vosko, Franz Aichner, Peter D Schellinger, Dietmar Schneider, Tobias Neumann-Haefelin, Joachim Röther, Antoni Davalos, Nils Wahlgren, Peter Verhamme |
Journal | Stroke
(Stroke)
Vol. 40
Issue 12
Pg. 3789-95
(Dec 2009)
ISSN: 1524-4628 [Electronic] United States |
PMID | 19834019
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Fibrinolytic Agents
- Peptide Fragments
- Placebos
- microplasmin
- Fibrinolysin
|
Topics |
- Acute Disease
- Aged
- Aged, 80 and over
- Brain Ischemia
(drug therapy, pathology)
- Cerebral Revascularization
(methods)
- Dose-Response Relationship, Drug
- Female
- Fibrinolysin
(administration & dosage, adverse effects, pharmacokinetics)
- Fibrinolytic Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Humans
- Injections, Intravenous
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Peptide Fragments
(administration & dosage, adverse effects, pharmacokinetics)
- Placebos
- Stroke
(drug therapy, pathology)
- Treatment Outcome
|